Aldeyra Therapeutics received a Complete Response Letter from the FDA for reproxalap, an investigational therapy for dry eye disease, due to concerns about efficacy and methodologic issues. The company plans additional trials to address FDA's recommendations and aims for potential NDA resubmission in mid-year 2025.
Source: Aldeyra Press Release
